Telitacicept

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE). It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases. In 2021, telitacicept was approved in China for the treatment of patients with active SLE.

It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS). Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).

Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE). It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases. In 2021, telitacicept was approved in China for the treatment of patients with active SLE.

It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS). Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).

Text derived from https://en.wikipedia.org/w/index.php?oldid=1252212192 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.